KOD Quote, Financials, Valuation and Earnings

Pfizer has a net margin of -- compared to Kodiak Sciences's net margin of 25.23%. Kodiak Sciences's return on equity of -- beat Pfizer's return on equity of 4.63%.

Kodiak Sciences has a consensus price target of $6.67, signalling downside risk potential of -14.64%. On the other hand Pfizer has an analysts' consensus of $31.78 which suggests that it could grow by 18.57%. Given that Pfizer has higher upside potential than Kodiak Sciences, analysts believe Pfizer is more attractive than Kodiak Sciences.

Kodiak Sciences has a beta of 2.113, which suggesting that the stock is 111.317% more volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

Kodiak Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.27% to investors and pays a quarterly dividend of $0.42 per share. Kodiak Sciences pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Kodiak Sciences quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.7B. Kodiak Sciences's net income of -$43.9M is lower than Pfizer's net income of $4.5B. Notably, Kodiak Sciences's price-to-earnings ratio is -- while Pfizer's PE ratio is 36.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences is -- versus 2.57x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -- compared to Kodiak Sciences's net margin of 36.03%. Kodiak Sciences's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Kodiak Sciences has a consensus price target of $6.67, signalling downside risk potential of -14.64%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,029.20 which suggests that it could grow by 44.61%. Given that Regeneron Pharmaceuticals has higher upside potential than Kodiak Sciences, analysts believe Regeneron Pharmaceuticals is more attractive than Kodiak Sciences.

Kodiak Sciences has a beta of 2.113, which suggesting that the stock is 111.317% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.098, suggesting its less volatile than the S&P 500 by 90.217%.

Kodiak Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Kodiak Sciences quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Kodiak Sciences's net income of -$43.9M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Kodiak Sciences's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences is -- versus 5.96x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Revance Therapeutics has a net margin of -- compared to Kodiak Sciences's net margin of -63.65%. Kodiak Sciences's return on equity of -- beat Revance Therapeutics's return on equity of --.

Kodiak Sciences has a consensus price target of $6.67, signalling downside risk potential of -14.64%. On the other hand Revance Therapeutics has an analysts' consensus of $7.64 which suggests that it could grow by 132.13%. Given that Revance Therapeutics has higher upside potential than Kodiak Sciences, analysts believe Revance Therapeutics is more attractive than Kodiak Sciences.

Kodiak Sciences has a beta of 2.113, which suggesting that the stock is 111.317% more volatile than S&P 500. In comparison Revance Therapeutics has a beta of 0.857, suggesting its less volatile than the S&P 500 by 14.274%.

Kodiak Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revance Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences pays -- of its earnings as a dividend. Revance Therapeutics pays out -- of its earnings as a dividend.

Kodiak Sciences quarterly revenues are --, which are smaller than Revance Therapeutics quarterly revenues of $59.9M. Kodiak Sciences's net income of -$43.9M is lower than Revance Therapeutics's net income of -$38.1M. Notably, Kodiak Sciences's price-to-earnings ratio is -- while Revance Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences is -- versus 1.24x for Revance Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals has a net margin of -- compared to Kodiak Sciences's net margin of -11.17%. Kodiak Sciences's return on equity of -- beat Vanda Pharmaceuticals's return on equity of -3.02%.

Kodiak Sciences has a consensus price target of $6.67, signalling downside risk potential of -14.64%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.17 which suggests that it could grow by 168.58%. Given that Vanda Pharmaceuticals has higher upside potential than Kodiak Sciences, analysts believe Vanda Pharmaceuticals is more attractive than Kodiak Sciences.

Kodiak Sciences has a beta of 2.113, which suggesting that the stock is 111.317% more volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.766, suggesting its less volatile than the S&P 500 by 23.396%.

Kodiak Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

Kodiak Sciences quarterly revenues are --, which are smaller than Vanda Pharmaceuticals quarterly revenues of $47.7M. Kodiak Sciences's net income of -$43.9M is lower than Vanda Pharmaceuticals's net income of -$5.3M. Notably, Kodiak Sciences's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences is -- versus 1.38x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.